Opportunity Information: Apply for PAR 19 288
This grant opportunity, PAR 19-288, is a limited-competition Funding Opportunity Announcement from the National Institutes of Health (NIH), specifically the National Institute on Aging (NIA), to continue operating the NIA Genome Center for Alzheimer's Disease (GCAD). The award mechanism is a U54 cooperative agreement, which usually means the funded Center would not just receive funds and operate independently, but would work closely with NIH program staff under a cooperative, partner-style relationship. The announcement is explicitly marked "Clinical Trial Not Allowed," so the work supported under this award is meant to be analytical, computational, and resource-oriented rather than involving the conduct of clinical trials.
The core purpose of the award is to keep GCAD running as the central hub that supports the Alzheimer's Disease Sequencing Project (ADSP). In practical terms, GCAD is expected to function as the focal point for critical data and analysis stages across ADSP, including quality control (QC) checking for sequencing and related genomic datasets, harmonizing data so that it can be compared and combined across multiple cohorts and studies, and conducting or coordinating meta-analyses that synthesize evidence across datasets. The FOA frames GCAD as supporting a major component of ADSP's overall analysis pipeline, meaning this is not a small add-on function; it is a central, enabling infrastructure for turning large-scale Alzheimer's genomics data into reliable results.
The scientific and public health aim is to strengthen a multidisciplinary, genetics-driven approach to understanding Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). By improving QC, harmonization, and meta-analysis across ADSP efforts, GCAD helps ensure that downstream findings about genetic risk factors, protective variants, biological pathways, and potential drug targets are based on well-curated and consistently processed data. The FOA emphasizes that the Center serves as a national resource with the specific goal of identifying potential avenues for therapeutic development and disease prevention, which positions GCAD as an enabling platform that supports discovery and translation rather than a single-investigator research project.
Eligibility is broad across U.S.-based organizations that commonly apply for NIH funding. Eligible applicant types include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than higher education institutions); for-profit organizations other than small businesses; and small businesses. The FOA also highlights additional eligible categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations and eligible federal agencies. U.S. territories or possessions are also included among the other eligible applicants listed.
At the same time, the announcement draws clear lines regarding foreign involvement. Non-domestic (non-U.S.) entities and non-domestic (non-U.S.) institutions are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply. However, "foreign components" as defined in the NIH Grants Policy Statement are allowed, meaning a U.S. applicant could potentially include certain kinds of international collaboration or activities if they meet NIH's definition and are properly justified and compliant, even though the applicant itself must be domestic.
From an administrative standpoint, the listing notes this is a discretionary grant in the health area and provides the CFDA number 93.866. The original closing date shown is September 25, 2022, and the creation date for the opportunity record is May 23, 2019. An award ceiling is not specified in the provided excerpt, and the expected number of awards is not listed. Overall, the opportunity is best understood as support for a centralized, high-impact genomics analysis and data coordination center that underpins national Alzheimer's sequencing efforts by ensuring data quality, consistency, and robust combined analyses across studies.Apply for PAR 19 288
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition: NIA Genome Center for Alzheimer's Disease (U54 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2019-05-23.
- Applicants must submit their applications by 2022-09-25. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs) - NIH/NIA Grant Opportunity PAR-19-288 (NIA Genome Center for Alzheimer's Disease, GCAD)
What is PAR-19-288?
PAR-19-288 is a limited-competition Funding Opportunity Announcement (FOA) from the National Institutes of Health (NIH), specifically the National Institute on Aging (NIA), to continue operating the NIA Genome Center for Alzheimer's Disease (GCAD).
Which NIH institute is sponsoring this opportunity?
The opportunity is sponsored by the National Institute on Aging (NIA), which is part of the National Institutes of Health (NIH).
What is the main purpose of this grant?
The main purpose is to continue operating GCAD as the central hub supporting the Alzheimer's Disease Sequencing Project (ADSP), particularly for key data and analysis functions such as quality control, data harmonization, and meta-analysis across ADSP datasets.
What role does GCAD play in the Alzheimer's Disease Sequencing Project (ADSP)?
GCAD is expected to function as a focal point for critical data and analysis stages across ADSP. This includes checking and improving data quality (QC), harmonizing genomic data so it can be compared and combined across multiple cohorts and studies, and conducting or coordinating meta-analyses that synthesize evidence across datasets.
Is this award intended to support a small standalone project?
No. The FOA frames GCAD as a central, enabling infrastructure and a major component of ADSP's overall analysis pipeline, rather than a small add-on or a single-investigator research project.
What award mechanism is used for PAR-19-288?
This FOA uses the U54 cooperative agreement mechanism.
What does it mean that the mechanism is a U54 cooperative agreement?
A U54 cooperative agreement typically indicates a partner-style relationship in which the funded Center works closely with NIH program staff, rather than operating entirely independently as would be more typical under some other grant mechanisms.
Are clinical trials allowed under this funding opportunity?
No. The announcement is explicitly marked "Clinical Trial Not Allowed," indicating that the work supported is intended to be analytical, computational, and resource-oriented rather than involving the conduct of clinical trials.
What types of activities are emphasized as part of GCAD's responsibilities?
Based on the FOA description, emphasized activities include quality control (QC) of sequencing and related genomic datasets, harmonizing data across cohorts and studies, and conducting or coordinating meta-analyses that integrate results across datasets.
What scientific or public health goals does this center support?
The center supports a multidisciplinary, genetics-driven approach to understanding Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). By improving QC, harmonization, and meta-analysis, GCAD helps support reliable identification of genetic risk factors, protective variants, biological pathways, and potential drug targets, and it is positioned as a national resource intended to enable therapeutic development and disease prevention.
Who is eligible to apply for this FOA?
Eligibility is broad across U.S.-based organizations that commonly apply for NIH funding. Eligible applicants include various government entities (state, county, city or township, and special district governments), independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments, and Native American tribal organizations that are not federally recognized.
Are nonprofit organizations eligible to apply?
Yes. Nonprofits with or without 501(c)(3) status (other than institutions of higher education) are listed as eligible applicant types.
Are for-profit organizations eligible to apply?
Yes. For-profit organizations other than small businesses are listed as eligible, and small businesses are also listed as eligible.
Are institutions that serve specific communities explicitly included as eligible applicants?
Yes. The FOA highlights additional eligible categories including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Are faith-based or community-based organizations eligible to apply?
Yes. Faith-based or community-based organizations are included among eligible applicants in the FOA description.
Are U.S. territories or possessions eligible to apply?
Yes. U.S. territories or possessions are included among the other eligible applicants listed.
Can a non-U.S. (foreign) organization apply as the applicant?
No. Non-domestic (non-U.S.) entities and non-domestic (non-U.S.) institutions are not eligible to apply as the applicant organization.
Can the non-U.S. component of a U.S. organization apply?
No. Non-domestic components of U.S. organizations are also not eligible to apply as the applicant.
Are any forms of international collaboration allowed?
Yes. While the applicant organization must be domestic, "foreign components" as defined in the NIH Grants Policy Statement are allowed. This indicates that a U.S. applicant may be able to include certain international collaboration or activities if they meet NIH's definition and are properly justified and compliant.
Is this a limited-competition opportunity?
Yes. The FOA is described as a limited-competition Funding Opportunity Announcement.
What is the CFDA number associated with this opportunity?
The listing provides CFDA number 93.866.
What general funding category does this opportunity fall under?
The listing notes this is a discretionary grant in the health area.
What is the opportunity record creation date?
The creation date for the opportunity record is May 23, 2019.
What is the closing date shown for this opportunity?
The original closing date shown is September 25, 2022.
Is an award ceiling specified in the provided information?
No. An award ceiling is not specified in the provided excerpt.
Is the expected number of awards listed in the provided information?
No. The expected number of awards is not listed in the provided excerpt.
How should this opportunity be understood in plain terms?
It is support for a centralized, high-impact genomics analysis and data coordination center that underpins national Alzheimer's sequencing efforts by ensuring data quality, consistency, and robust combined analyses across studies.
Browse more opportunities from the same category: Health
Next opportunity: Assess Abundance of American Eel within Delaware River
Previous opportunity: GLNF-CESU- Interpretation of Ecosystem Vulnerability Assessment- APIS
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 19 288
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 19 288) also looked into and applied for these:
| Funding Opportunity |
|---|
| Understanding Senescence in Brain Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 025 Funding Number: RFA AG 20 025 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) Apply for PAR 19 289 Funding Number: PAR 19 289 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Adolescent Health and Well-Being in Urban Areas Apply for BAA NIGERIA HPNIAH 2019 Funding Number: BAA NIGERIA HPNIAH 2019 Agency: Nigeria USAID-Abuja Category: Health Funding Amount: Case Dependent |
| Immunobiology of Xenotransplantation (U01 Clinical Trial Not Allowed) Apply for RFA AI 19 042 Funding Number: RFA AI 19 042 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Immunobiology of Xenotransplantation (U19 Clinical Trial Not Allowed) Apply for RFA AI 19 043 Funding Number: RFA AI 19 043 Agency: National Institutes of Health Category: Health Funding Amount: $1,200,000 |
| Oscillatory Patterns of Gene Expression in Aging and Alzheimers Disease (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 040 Funding Number: RFA AG 20 040 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Exploratory Grant for NIA Alzheimers Disease Research Center (P20 Clinical Trial Not Allowed) Apply for RFA AG 20 023 Funding Number: RFA AG 20 023 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis (U01 Clinical Trial Not Allowed) Apply for RFA HL 20 007 Funding Number: RFA HL 20 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Interpersonal Processes in Alzheimer's Disease and Related Dementias Clinical Interactions and Care Partnerships (R01 Clinical Trial Optional) Apply for RFA AG 20 006 Funding Number: RFA AG 20 006 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Cardiovascular Developmental Biology Data Resource Center (U01 - Clinical Trial Not Allowed) Apply for RFA HL 20 017 Funding Number: RFA HL 20 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Biology of Aging in Reproductive Tissues (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 036 Funding Number: RFA AG 20 036 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Pediatric Cardiac Genomics Consortium (U01 - Clinical Trial Not Allowed) Apply for RFA HL 20 015 Funding Number: RFA HL 20 015 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Diversity Program Consortium Dissemination and Translation Awards (U01 - Clinical Trial Not Allowed) Apply for RFA RM 19 003 Funding Number: RFA RM 19 003 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed) Apply for PAR 19 296 Funding Number: PAR 19 296 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Research to Understand and Inform Interventions that Promote the Research Careers of Individuals in the Biomedical Sciences (R01 - Clinical Trial Not Allowed) Apply for PAR 19 295 Funding Number: PAR 19 295 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional) Apply for PAR 19 297 Funding Number: PAR 19 297 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Aging, Driving and Early Detection of Dementia (R01 Clinical Trial Optional) Apply for RFA AG 20 022 Funding Number: RFA AG 20 022 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Limited Competition: Continuation of the Center for Genomic Studies on Mental Disorders (U24 Clinical Trial Not Allowed) Apply for RFA MH 20 215 Funding Number: RFA MH 20 215 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mechanistic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01 Clinical Trial Not Allowed) Apply for RFA NS 19 039 Funding Number: RFA NS 19 039 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Characterization of Marmosets as Models of Aging and Age-Related Diseases (U34 Clinical Trial Not Allowed) Apply for RFA AG 20 007 Funding Number: RFA AG 20 007 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 19 288", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.